Product image of Maraviroc Waymade (Maraviroc) supplied by GNH India

Maraviroc Waymade

Active Ingredient:
Maraviroc
Origin:
EU

Maraviroc Waymade (Maraviroc)

Maraviroc, the active ingredient in Maraviroc Waymade, is a CCR5 antagonist presented as an oral formulation for oral use. It is indicated for the treatment of CCR5‑tropic HIV‑1 infection when used in combination with other antiretroviral agents, helping to suppress viral replication in affected patients.

GNH India supplies Maraviroc Waymade as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. All shipments are accompanied by full documentation and temperature‑controlled logistics where required.

Manufacturer / TM Owner

Waymade B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Maraviroc is a CCR5 antagonist used in antiretroviral therapy to target HIV‑1 strains that utilize the CCR5 co‑receptor.

  • CCR5‑tropic HIV‑1 infection: used in combination with other antiretroviral agents to achieve viral suppression.
  • Treatment‑experienced HIV patients: added when resistance to other classes develops, provided the virus remains CCR5‑tropic.
  • Initial antiretroviral regimen: incorporated as part of a combination regimen for newly diagnosed patients with confirmed CCR5‑tropic virus.

How It Works

  • Maraviroc selectively binds to the CCR5 chemokine receptor on the surface of CD4+ T‑lymphocytes, blocking the interaction between the receptor and the HIV‑1 envelope glycoprotein gp120. By preventing this binding, the drug inhibits the entry of CCR5‑tropic HIV‑1 into host cells, thereby halting a critical step in the viral replication cycle and reducing viral load when used with other antiretrovirals.

Side Effects

Maraviroc may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Nausea: occasional gastrointestinal upset.
  • Diarrhea: loose stools, usually transient.
  • Fatigue: general tiredness.

Serious or Rare Side Effects

  • Liver injury: elevated transaminases or hepatitis.
  • Severe allergic reaction: anaphylaxis or angioedema.
  • Immune reconstitution inflammatory syndrome: worsening of opportunistic infections.

Precautions & Warnings

When prescribing Maraviroc, clinicians should observe several precautionary measures to ensure safe use.

  • Assess CCR5 tropism before initiating: confirm the virus uses the CCR5 co‑receptor.
  • Monitor liver function: perform baseline and periodic transaminase tests.
  • Review concomitant medications: evaluate for potential drug‑drug interactions.
  • Consider pregnancy and breastfeeding status: weigh potential risks against benefits.
  • Store at ambient temperature: keep in the original packaging, protect from moisture.

Avoid Interactions

Maraviroc interacts with several agents that can alter its plasma concentrations or increase toxicity.

Major Interactions (Avoid)

  • Protease inhibitors boosted with ritonavir: increase maraviroc exposure significantly.
  • Strong CYP3A inducers such as rifampin: markedly reduce maraviroc levels.
  • Drugs that prolong QT interval: may increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

  • Statins like simvastatin: may have increased concentrations; monitor lipid levels.
  • Anticonvulsants such as carbamazepine: may lower maraviroc exposure; adjust dose if needed.

Frequently Asked Questions

Maraviroc Waymade is used as part of combination antiretroviral therapy for patients infected with CCR5‑tropic HIV‑1. It helps to block viral entry into CD4+ cells, thereby reducing viral load and supporting immune system recovery when used with other approved HIV medicines.

Maraviroc works by selectively binding to the CCR5 co‑receptor on the surface of CD4+ T‑lymphocytes. This blocks the interaction between CCR5 and the HIV‑1 envelope protein gp120, preventing the virus from entering and infecting the cell, which interrupts the replication cycle.

The dosage of Maraviroc Waymade is individualized by the prescribing clinician based on factors such as viral tropism, concomitant medications, liver function and patient weight. Only a qualified healthcare professional should determine the appropriate regimen.

Data on Maraviroc use during pregnancy and lactation are limited. Clinicians should evaluate the potential benefits against possible risks to the fetus or infant and may consider alternative therapies if safety cannot be assured.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maraviroc belongs to the CCR5 antagonist class, targeting viral entry, whereas integrase inhibitors block viral DNA integration and protease inhibitors prevent viral protein processing. Maraviroc is effective only against CCR5‑tropic strains, so tropism testing is required, while other classes have broader activity across HIV subtypes.

Store Maraviroc Waymade at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and avoid exposing it to extreme heat or humidity to maintain potency.

Maraviroc is taken orally, usually with food to improve absorption. The tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include liver injury (elevated transaminases or hepatitis), severe allergic reactions such as anaphylaxis, and immune reconstitution inflammatory syndrome, which can exacerbate existing opportunistic infections after immune recovery.

Patients with confirmed CXCR4‑tropic or dual‑tropic HIV‑1, those with severe hepatic impairment, or individuals taking contraindicated strong CYP3A inducers should avoid Maraviroc. Additionally, patients with known hypersensitivity to maraviroc or any excipients should not use the product.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Maraviroc

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT